Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
65 巻, 10 号
選択された号の論文の24件中1~24を表示しています
ORIGINAL ARTICLES
  • Kanako Sato, Yoko Irie, Hiroaki Asai, Saori Yoshioka, Keisuke Murakawa ...
    2026 年65 巻10 号 p. 1334-1341
    発行日: 2026/05/15
    公開日: 2026/05/15
    [早期公開] 公開日: 2025/10/09
    ジャーナル オープンアクセス

    Objective To investigate the additive effects of semaglutide on liver function indicators in patients with type 2 diabetes mellitus (T2DM) complicated by metabolic dysfunction-associated steatotic liver disease (MASLD), who received sodium-glucose cotransporter 2 inhibitors (SGLT2-Is).

    Methods Liver function indicators at baseline were compared with those 6 months after the initiation of semaglutide.

    Patients Forty-seven patients (mean age, 56.2±10.4 years; 74.5% men) with T2DM complicated by MASLD who were prescribed SGLT2-Is continuously for at least 12 months were retrospectively selected.

    Results Six months of semaglutide treatment significantly decreased body weight (BW; 80.9±16.4 kg to 77.3±17.0 kg, p<0.001), body mass index (BMI; 28.9±4.5 kg/m2 to 27.7±4.6 kg/m2, p<0.001), and the levels of glycated hemoglobin (HbA1c; 7.4±0.7% to 6.9±0.7%, p<0.001), aspartate aminotransferase (AST; 30.4±15.9 U/L to 26.3±12.5 U/L, p=0.014), alanine aminotransferase (ALT; 42.4±28.7 U/L to 35.7±22.8 U/L, p=0.022), and gamma-glutamyl transpeptidase (γ-GTP; 46.5±36.8 U/L to 38.0±30.0 U/L, p=0.001). The fibrosis-4 index, an indicator of liver fibrosis, did not improve. Changes in ALT levels were significantly correlated with changes in metabolic parameters, including BW (p=0.004), BMI (p=0.004), HbA1c (p=0.005), and triglycerides (p=0.011).

    Conclusion The addition of semaglutide to SGLT2-Is reduced liver enzyme levels in patients with T2DM complicated with MASLD. Future randomized controlled trials are needed to investigate the additive effects of semaglutide on MASLD in patients with T2DM receiving SGLT2-Is.

  • Ryuhei Sato, Tomohiro Handa, Kiminobu Tanizawa, Toyohiro Hirai
    2026 年65 巻10 号 p. 1342-1351
    発行日: 2026/05/15
    公開日: 2026/05/15
    [早期公開] 公開日: 2025/10/02
    ジャーナル オープンアクセス

    Objective The extent to which support benefits family caregivers and whether healthcare professionals effectively fulfill this role remains unclear. This study investigated whether the presence or absence of a supportive person affects the health-related quality of life (HRQOL) of family caregivers of patients with interstitial lung disease (ILD) and whether support from healthcare professionals influences HRQOL.

    Methods This cross-sectional study was conducted at Kyoto University Hospital between April 2020 and March 2021. A supportive person was defined as someone available to discuss personal concerns. Caregivers' HRQOL was measured using the Medical Outcomes Study 36-Item Short-Form Health Survey version 2 (SF-36v2), and scores were compared between those with and without support. Further comparisons were made between caregivers who did and did not identify healthcare professionals as supportive persons.

    Patients This study included outpatients with ILD and their caregivers.

    Results Among the family caregivers, 78.3% reported having a supportive person. However, their presence was not significantly associated with the SF-36v2 scores. Compared to caregivers without a healthcare professional as a supportive person, those who identified healthcare professionals in this role had significantly higher vitality and mental component summary SF-36v2 scores (p=0.031 and p=0.012, respectively).

    Conclusion Approximately 80% of the family caregivers of patients with ILD reported having a supportive person. While the general presence of a supportive person did not impact HRQOL scores, those who had healthcare professionals as supportive persons demonstrated a higher mental HRQOL.

CASE REPORTS
PICTURES IN CLINICAL MEDICINE
LETTERS TO THE EDITOR
feedback
Top